Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 8 of 8 entries
View as:

A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT03830411 Org: User:
Start: 03/13/19 End: 06/30/22 Due: 06/30/23

A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05749042 Org: User:
Start: 01/18/23 End: 01/18/25 Due: 01/18/26

A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy

Phase: N/A Priority: Normal
NCT ID: NCT06467500 Org: User:
Start: 03/01/24 End: 12/30/26 Due: 12/30/27

A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04411706 Org: User:
Start: 06/21/20 End: 06/01/22 Due: 06/01/23

The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution.

Phase: N/A Priority: Normal
NCT ID: NCT06029829 Org: User:
Start: 01/12/23 End: 06/30/24 Due: 06/30/25

A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04367909 Org: User:
Start: 06/21/20 End: 12/01/22 Due: 12/01/23

A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.

Phase: N/A Priority: Normal
NCT ID: NCT03863483 Org: User:
Start: 03/26/19 End: 12/31/22 Due: 12/31/23

Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T Lymphocytes

Phase: N/A Priority: Normal
NCT ID: NCT05792995 Org: User:
Start: 12/21/21 End: 03/01/23 Due: 03/01/24